Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Department of Pharmacy, St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan.
Nutr Cancer. 2022;74(2):539-545. doi: 10.1080/01635581.2021.1902542. Epub 2021 Mar 23.
Limited information is available regarding the impact of body weight loss (BWL) in patients with advanced gastric cancer (AGC) who receive second-line chemotherapy. We retrospectively reviewed data for consecutive AGC patients who received second-line treatment with taxane-based chemotherapy at our institution between January 2014 and September 2018. We calculated variables, including percent BWL per month during chemotherapy (%BWL/m), and analyzed the correlations between BWL and other clinicopathological parameters with survival. Forty-four AGC patients were registered (median age, 67.5 years; females, = 16 [36.3%]; severe ascites, = 12 [27.3%]). The median overall survival was significantly shorter among patients with a %BWL/m of 1% or more, compared with patients with less weight loss (6.3 mo, vs. 12.3 mo, = 0.038). The %BWL/m (≥1% vs. <1%) was significantly correlated with survival in a univariate analysis (HR = 2.11, = 0.04), and the survival period was shorter for patients with severe ascites (HR = 1.92; 95% CI, 0.90-3.90) and if their %BWL/m was 1% or more (HR = 2.01; 95% CI, 0.98-4.10) in a multivariate analysis. In conclusion, BWL during second-line chemotherapy was associated with a poor prognosis among patients with AGC.
关于接受二线化疗的晚期胃癌（AGC）患者体质量减轻（BWL）对其的影响，相关信息有限。我们对 2014 年 1 月至 2018 年 9 月期间在我院接受二线紫杉烷类化疗的 AGC 患者的连续数据进行了回顾性分析。我们计算了化疗期间每月体质量减轻百分比（%BWL/m）等变量，并分析了 BWL 与其他临床病理参数与生存的相关性。共登记了 44 例 AGC 患者（中位年龄 67.5 岁；女性 16 例[36.3%]；严重腹水 12 例[27.3%]）。与体质量减轻较少的患者相比，%BWL/m 为 1%或更高的患者总生存期明显更短（6.3 个月比 12.3 个月，= 0.038）。在单因素分析中，%BWL/m（≥1%比<1%）与生存显著相关（HR=2.11，= 0.04），且严重腹水患者（HR=1.92；95%CI，0.90-3.90）和 %BWL/m 为 1%或更高的患者（HR=2.01；95%CI，0.98-4.10）的生存时间更短。总之，二线化疗期间的 BWL 与 AGC 患者的预后不良相关。
